Ravit Geva

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto et al. · Journal of Clinical Oncology · 2019 · 2.8K citations · Full text

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Rita Nanda, Laura Q.M. Chow, Elizabeth Claire Dees et al. · Journal of Clinical Oncology · 2016 · 1.4K citations · Full text

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

Kei Muro, Hyun Cheol Chung, Veena Shankaran et al. · The Lancet Oncology · 2016 · 1.1K citations · Full text

Gastrointestinal Oncology, Medicine, Pathology +5

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

Dung T. Le, Tae Won Kim, Eric Van Cutsem et al. · Journal of Clinical Oncology · 2019 · 975 citations · Full text

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5